Načítá se...

Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines

Treatment of patients with advanced sarcoma remains challenging due to lack of effective medicine, with the development of novel drugs being of keen interest. A pan-PI3K inhibitor, ZSTK474, has been evaluated in clinical trials against a range of advanced solid tumors, with clinical benefit shown in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Namatame, Nachi, Tamaki, Naomi, Yoshizawa, Yuya, Okamura, Mutsumi, Nishimura, Yumiko, Yamazaki, Kanami, Tanaka, Miwa, Nakamura, Takuro, Semba, Kentaro, Yamori, Takao, Yaguchi, Shin-ichi, Dan, Shingo
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205545/
https://ncbi.nlm.nih.gov/pubmed/30416685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26216
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!